What is Genenta Science?
Genenta Science is a biotechnology company headquartered in Milan, Italy, dedicated to pioneering gene therapies derived from hematopoietic stem cells. Their primary focus is on developing treatments for solid tumors, a challenging area within oncology. The company's approach involves leveraging advanced genetic engineering techniques to modify stem cells, with the goal of creating more effective and targeted therapies for patients with difficult-to-treat cancers. Their work places them at the forefront of regenerative medicine and cancer treatment innovation.
How much funding has Genenta Science raised?
Genenta Science has raised a total of $56M across 4 funding rounds:
Series A
$11M
Series B
$8.4M
Other Financing Round
$14.7M
Other Financing Round
$21.9M
Series A (2015): $11M with participation from Banca Esperia
Series B (2017): $8.4M, investors not publicly disclosed
Other Financing Round (2019): $14.7M supported by Bormioli, Fumagalli, Fidim, and Qinzhan Investment Management
Other Financing Round (2025): $21.9M featuring ENEA Tech e Biomedical
Key Investors in Genenta Science
ENEA Tech e Biomedical
ENEA Tech e Biomedical is a foundation focused on investments in technology transfer and biomedical research, aiming to foster innovation and connect research with industry. It supports high-potential startups and SMEs in the biotech sector.
Banca Esperia
Banca Esperia is an Italian bank, previously a joint venture involving Mediobanca and Banca Mediolanum, providing financial services and investment support.
Bormioli
Bormioli is an entity that has participated in previous financing rounds for Genenta Science, contributing to the company's capital growth.
What's next for Genenta Science?
With the recent major strategic investment, Genenta Science is poised to accelerate its development pipeline and potentially expand its clinical trial programs. The substantial capital infusion, indicated by $56M, suggests a significant growth phase for the company, likely enabling further research, development, and regulatory advancements. This strategic backing is critical for a clinical-stage biotechnology company aiming to bring novel gene therapies to market, positioning Genenta Science for future milestones and potential commercialization.
See full Genenta Science company page
